Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

Major investors Nvidia and Novo Holdings A/S have fully exited their positions in Recursion Pharmaceuticals (NasdaqGS:RXRX), signaling a shift in institutional backing. Recursion has acquired full ...

By Joseph Tulloch For years, AI safety experts have been warning of a future moment where AI models become advanced enough to ...

As the program engages more directly with global concerns such as the climate crisis, he will lead the way.

Apheris's ADMET Network will combine proprietary datasets in a privacy-preserving environment to accelerate AI drug discovery models.

T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow ...

The resulting outcome is that you have A.I. systems that have learned what it means to solve a problem that takes quite a ...

Meanwhile, Nvidia has maintained its investment in CoreWeave, and even announced an additional $2 billion investment in the ...

If you were looking for me last Saturday evening, you’d have found me at the Irene and Alan Wurtzel Theater for the TIMARA faculty recital, titled “Signal: Noise.” The Wurtzel Theater’s vibe was ...